A federal trial court in California entered a consent injunction and dismissal order March 27 in Depomed Inc.’s lawsuit alleging Lupin Pharmaceuticals Inc. and Lupin Ltd. infringed a patent for the diabetes medication Glumetza (metformin) (Depomed Inc. v. Lupin Pharmaceuticals Inc.).
Depomed filed suit after Lupin notified it that it had filed an abbreviated new drug application with the Food and Drug Administration, seeking approval to market generic Glumetza in 500 milligram and 1000 mg tablets.
The parties consented to an injunction that stops Lupin from manufacturing, using, offering to sell, or selling within the United States and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.